Department of Emergency Medicine, University of Michigan, 24 Frank Lloyd Wright Drive, PO Box 381, Ann Arbor, MI 48106-0381, USA.
Stroke. 2010 Sep;41(9):2026-32. doi: 10.1161/STROKEAHA.110.581942. Epub 2010 Aug 12.
The objective of this study was to determine the baseline proportion of emergency physicians with favorable attitudes and beliefs toward intravenous tissue plasminogen activator (tPA) use in a cohort of randomly selected Michigan hospitals.
Two hundred seventy-eight emergency physicians from 24 hospitals were surveyed. A confidential, self-administered, pilot-tested survey assessing demographics, practice environment, attitudes, and beliefs regarding tPA use in stroke was used. Main outcome measures assessed belief in a legal standard of care, likelihood of use in an ideal setting, comfort in use without a specialist consultation, and belief that science on tPA use is convincing. ORs with robust 95% CIs (adjusted for clustering) were calculated to quantify the association between responses and physician- and hospital-level characteristics.
One hundred ninety-nine surveys completed (gross response rate 71.6%). Ninety-nine percent (95% CI: 97.8 to 100) indicated use of tPA in eligible patients represented either acceptable or ideal patient care. Twenty-seven percent (95% CI: 21.7 to 32.3) indicated use of tPA represented a legal standard of care. Eighty-three percent (95% CI: 78.5 to 87.5) indicated they were "likely" or "very likely" to use tPA given an ideal setting. When asked about using tPA without a consultation, 65% (95% CI: 59.3 to 70.7) indicated they were uncomfortable. Forty-nine percent (95% CI: 43.0 to 55.0) indicated the science regarding use of tPA in stroke is convincing with 30% remaining neutral. Characteristics associated with favorable attitudes included non-emergency medicine board certification; older age, and a smaller hospital practice environment.
In this cohort, emergency physician attitudes and beliefs toward intravenous tPA use in stroke are considerably more favorable than previously reported.
本研究旨在确定一组随机选择的密歇根州医院中急诊医师对静脉注射组织型纤溶酶原激活剂(tPA)使用的有利态度和信念的基线比例。
对 24 家医院的 278 名急诊医师进行了调查。使用了一份机密的、自我管理的、经过试点测试的调查,评估了人口统计学、实践环境、对卒中使用 tPA 的态度和信念。主要结局指标评估了对法律护理标准的信念、在理想环境下使用的可能性、在没有专家咨询的情况下使用的舒适度,以及对 tPA 使用的科学证据的信心。使用稳健的 95%CI(调整聚类)计算了 OR,以量化回答与医师和医院特征之间的关联。
完成了 199 份调查(总应答率为 71.6%)。99%(95%CI:97.8 至 100)的人表示,在符合条件的患者中使用 tPA 代表可接受或理想的患者护理。27%(95%CI:21.7 至 32.3)的人表示,使用 tPA 代表法律护理标准。83%(95%CI:78.5 至 87.5)的人表示,在理想的情况下,他们“很可能”或“非常可能”使用 tPA。当被问及在没有咨询的情况下使用 tPA 时,65%(95%CI:59.3 至 70.7)的人表示他们感到不舒服。49%(95%CI:43.0 至 55.0)的人表示,关于卒中使用 tPA 的科学证据令人信服,30%的人持中立态度。与有利态度相关的特征包括非急诊医学委员会认证;年龄较大,以及较小的医院实践环境。
在本队列中,急诊医师对卒中静脉内使用 tPA 的态度和信念比以前报道的更为有利。